GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imunon Inc (FRA:CBO) » Definitions » Institutional Ownership

Imunon (FRA:CBO) Institutional Ownership : 1.31% (As of Apr. 27, 2025)


View and export this data going back to 2012. Start your Free Trial

What is Imunon Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Imunon's institutional ownership is 1.31%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Imunon's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Imunon's Float Percentage Of Total Shares Outstanding is 98.62%.


Imunon Institutional Ownership Historical Data

The historical data trend for Imunon's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imunon Institutional Ownership Chart

Imunon Historical Data

The historical data trend for Imunon can be seen below:

2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 1.00 0.99 0.64 1.00 1.10 1.10 1.33 1.32 1.31 1.31

Imunon Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Imunon Business Description

Industry
Traded in Other Exchanges
Address
997 Lenox Drive, Suite 100, Lawrenceville, NJ, USA, 08648
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

Imunon Headlines

No Headlines